跳转至内容
Merck
CN
  • Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models.

Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models.

Acta pharmacologica Sinica (2011-11-08)
Zhi-fei Wang, Emily Bame Fessler, De-Maw Chuang
摘要

The mood stabilizers lithium, valproate and lamotrigine are traditionally used to treat bipolar disorder. However, accumulating evidence suggests that these drugs have broad neuroprotective properties and may therefore be promising therapeutic agents for the treatment of neurodegenerative diseases, including stroke. Lithium, valproate and lamotrigine exert protective effects in diverse experimental stroke models by acting on their respective primary targets, ie, glycogen synthase kinase-3, histone deacetylases and voltage-gated sodium channels, respectively. This article reviews the most recent findings regarding the underlying mechanisms of these phenomena, which will pave the way for clinical investigations that use mood stabilizers to treat stroke. We also propose several future research avenues that may extend our understanding of the benefits of lithium, valproate and lamotrigine in improving stroke outcomes.

材料
货号
品牌
产品描述

Sigma-Aldrich
拉莫三嗪, ≥98%, powder
Supelco
拉莫三嗪, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Lamotrigine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
拉莫三嗪, United States Pharmacopeia (USP) Reference Standard
拉莫三嗪, European Pharmacopoeia (EP) Reference Standard
峰鉴别用拉莫三嗪, European Pharmacopoeia (EP) Reference Standard
拉莫三嗪, European Pharmacopoeia (EP) Reference Standard